Oncotarget

Research Perspectives:

Rejuvenating immunity: “anti-aging drug today” eight years later

Mikhail V. Blagosklonny _

PDF |  HTML  |  Author Information  |  Order a Reprint

Oncotarget. 2015; 6:19405-19412. https://doi.org/10.18632/oncotarget.3740

Metrics: PDF 1555 views  |   HTML 2048 views  |   ?  


Abstract

Mikhail V. Blagosklonny1

1 Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

Correspondence to:

Mikhail V. Blagosklonny, email:

Keywords: mTOR, TOR, gerosuppression, rapalogs, lifespan, longevity, diseases

Received: February 16, 2015 Accepted: March 28, 2015 Published: March 31, 2015

Abstract

The 2014 year ended with celebration: Everolimus, a rapamycin analog, was shown to improve immunity in old humans, heralding ‘a turning point’ in research and new era in human quest for immortality. Yet, this turning point was predicted a decade ago. But what will cause human death, when aging will be abolished?

Author Information

Mikhail V. Blagosklonny
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3740